Gene therapy has undergone transformative enhancements over the last 20 years, with improvements to technologies and advances in the pipeline that aim to invigorate the field in its second generation. A dozen products have made it to various markets worldwide, including several within the last few years, and more are expected to gain approval soon. The pipeline is dominated by oncology ex vivo targets, but there are many approaches being pursued by key players outside of this core area.

This Datamonitor Healthcare report contains a Strategy module.